Advertisement

Oral Signs of Vesiculobullous and Autoimmune Disease

  • Michael Z. Wang
  • Julia S. LehmanEmail author
  • Roy Steele RogersIII
Chapter

Abstract

This chapter is focused on the oral manifestations of vesiculobullous and autoimmune diseases. These diseases often share similar oral presentations with subtle differences. Therefore, eliciting a detailed medical history and a thorough oral examination are necessary, while supporting tests including serologies, biopsies, as well as direct and indirect immunofluorescence are often valuable. Examination of cutaneous skin and non-oral mucosa may offer additional diagnostic and prognostic insights. Oral vesiculobullous and autoimmune diseases can lead to debilitating morbidities such as pain and poor oral intake. These diseases may also serve as windows to internal diseases such as infection and malignancy, which necessitates multidisciplinary care.

This chapter describes the epidemiology, etiopathogenesis, clinical manifestations, differential diagnosis, and treatments of oral vesiculobullous and autoimmune diseases, with an emphasis on their oral signs and symptoms.

Keywords

Vesiculobullous Autoimmune Pemphigus Pemphigoid Paraneoplastic Lichen planus Erythema multiforme Steven Johnson syndrome Toxic epidermal necrolysis Dermatitis herpetiformis Linear IgA bullous dermatosis Epidermolysis bullosa Angina bullosa hemorrhagica Vitiligo 

References

  1. 1.
    Ahmed AR, Graham J, Jordon RE, Provost TT. Pemphigus: current concepts. Ann Intern Med. 1980;92(3):396–405.Google Scholar
  2. 2.
    Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin. 1993;11(3):429–52.PubMedGoogle Scholar
  3. 3.
    Ahmed AR, Nguyen T, Kaveri S, Spigelman ZS. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up. Int Immunopharmacol. 2016;34:25–31.PubMedGoogle Scholar
  4. 4.
    Sagi L, Sherer Y, Trau H, Shoenfeld Y. Pemphigus and infectious agents. Autoimmun Rev. 2008;8(1):33–5.PubMedGoogle Scholar
  5. 5.
    Krain LS. Pemphigus. Epidemiologic and survival characteristics of 59 patients, 1955–1973. Arch Dermatol. 1974;110(6):862–5.PubMedGoogle Scholar
  6. 6.
    Helander SD, Rogers RS 3rd. The sensitivity and specificity of direct immunofluorescence testing in disorders of mucous membranes. J Am Acad Dermatol. 1994;30(1):65–75.PubMedGoogle Scholar
  7. 7.
    Shamim T, Varghese VI, Shameena PM, Sudha S. Pemphigus vulgaris in oral cavity: clinical analysis of 71 cases. Med Oral Patol Oral Cir Bucal. 2008;13(10):E622–6.PubMedGoogle Scholar
  8. 8.
    Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772–9.PubMedGoogle Scholar
  9. 9.
    Robinson JC, Lozada-Nur F, Frieden I. Oral pemphigus vulgaris: a review of the literature and a report on the management of 12 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(4):349–55.PubMedGoogle Scholar
  10. 10.
    Ding X, Aoki V, Mascaro JM Jr, Lopez-Swiderski A, Diaz LA, Fairley JA. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol. 1997;109(4):592–6.PubMedGoogle Scholar
  11. 11.
    Atzmony L, Hodak E, Gdalevich M, Rosenbaum O, Mimouni D. Treatment of pemphigus vulgaris and pemphigus foliaceus: a systematic review and meta-analysis. Am J Clin Dermatol. 2014;15(6):503–15.PubMedGoogle Scholar
  12. 12.
    Harman KE, Seed PT, Gratian MJ, Bhogal BS, Challacombe SJ, Black MM. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels. Br J Dermatol. 2001;144(4):775–80.PubMedGoogle Scholar
  13. 13.
    Scully C, Paes De Almeida O, Porter SR, Gilkes JJ. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol. 1999;140(1):84–9.PubMedGoogle Scholar
  14. 14.
    Mignogna MD, Lo Muzio L, Galloro G, Satriano RA, Ruocco V, Bucci E. Oral pemphigus: clinical significance of esophageal involvement: report of eight cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(2):179–84.PubMedGoogle Scholar
  15. 15.
    Dagistan S, Goregen M, Miloglu O, Cakur B. Oral pemphigus vulgaris: a case report with review of the literature. J Oral Sci. 2008;50(3):359–62.PubMedGoogle Scholar
  16. 16.
    Meurer M, Millns JL, Rogers RS 3rd, Jordon RE. Oral pemphigus vulgaris. A report of ten cases. Arch Dermatol. 1977;113(11):1520–4.PubMedGoogle Scholar
  17. 17.
    Sirois D, Leigh JE, Sollecito TP. Oral pemphigus vulgaris preceding cutaneous lesions: recognition and diagnosis. J Am Dent Assoc. 2000;131(8):1156–60.PubMedGoogle Scholar
  18. 18.
    Vinay K, Kanwar AJ, Mittal A, Dogra S, Minz RW, Hashimoto T. Intralesional rituximab in the treatment of refractory oral pemphigus vulgaris. JAMA Dermatol. 2015;151(8):878–82.PubMedGoogle Scholar
  19. 19.
    Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol. 1996;34(4):645–52.PubMedGoogle Scholar
  20. 20.
    Rogers RS 3rd, Van Hale HM. Immunopathologic diagnosis of oral mucosal inflammatory diseases. Australas J Dermatol. 1986;27(2):51–7.PubMedGoogle Scholar
  21. 21.
    Harman KE, Albert S, Black MM, British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003;149(5):926–37.PubMedGoogle Scholar
  22. 22.
    Michailidou EZ, Belazi MA, Markopoulos AK, Tsatsos MI, Mourellou ON, Antoniades DZ. Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: retrospective study of 129 patients. Int J Dermatol. 2007;46(4):356–61.PubMedGoogle Scholar
  23. 23.
    Tabrizi MN, Chams-Davatchi C, Esmaeeli N, Noormohammadpoor P, Safar F, Etemadzadeh H, et al. Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double-blind, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2007;21(1):79–84.PubMedGoogle Scholar
  24. 24.
    Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990;323(25):1729–35.PubMedGoogle Scholar
  25. 25.
    Czernik A, Camilleri M, Pittelkow MR, Grando SA. Paraneoplastic autoimmune multiorgan syndrome: 20 years after. Int J Dermatol. 2011;50(8):905–14.PubMedGoogle Scholar
  26. 26.
    Poot AM, Diercks GF, Kramer D, Schepens I, Klunder G, Hashimoto T, et al. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol. 2013;169(5):1016–24.PubMedGoogle Scholar
  27. 27.
    Yong AA, Tey HL. Paraneoplastic pemphigus. Australas J Dermatol. 2013;54(4):241–50.PubMedGoogle Scholar
  28. 28.
    Poot AM, Siland J, Jonkman MF, Pas HH, Diercks GF. Direct and indirect immunofluorescence staining patterns in the diagnosis of paraneoplastic pemphigus. Br J Dermatol. 2016;174(4):912–5.PubMedGoogle Scholar
  29. 29.
    Joly P, Richard C, Gilbert D, Courville P, Chosidow O, Roujeau JC, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43(4):619–26.PubMedGoogle Scholar
  30. 30.
    Helou J, Allbritton J, Anhalt GJ. Accuracy of indirect immunofluorescence testing in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 1995;32(3):441–7.PubMedGoogle Scholar
  31. 31.
    Murrell DF. Blistering diseases: clinical features, pathogenesis, treatment. New York: Springer; 2015. p. XXI.. 752Google Scholar
  32. 32.
    Schoen H, Foedinger D, Derfler K, Amann G, Rappersberger K, Stingl G, Volc-Platzer B. Immunoapheresis in paraneoplastic pemphigus. Arch Dermatol. 1998;134(6):706–10.PubMedGoogle Scholar
  33. 33.
    Jansen T, Plewig G, Anhalt GJ. Paraneoplastic pemphigus with clinical features of erosive lichen planus associated with Castleman’s tumor. Dermatology. 1995;190(3):245–50.PubMedGoogle Scholar
  34. 34.
    Bech R, Baumgartner-Nielsen J, Peterslund NA, Steiniche T, Bang K, Deleuran M, et al. Alemtuzumab (ALZ) is an effective treatment for both primary and relapsed severe paraneoplastic pemphigus (PNP) associated to B-cell chronic lymphocytic leukemia (CLL). Blood. 2007;110(11):1.Google Scholar
  35. 35.
    Horn TD, Anhalt GJ. Histologic features of paraneoplastic pemphigus. Arch Dermatol. 1992;128(8):1091–5.PubMedGoogle Scholar
  36. 36.
    Nousari HC, Brodsky RA, Jones RJ, Grever MR, Anhalt GJ. Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol. 1999;40(5 Pt 1):750–4.PubMedGoogle Scholar
  37. 37.
    Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol. 2004;40(6):553–62.PubMedGoogle Scholar
  38. 38.
    Ghigliotti G, Di Zenzo G, Cozzani E, Rongioletti F, De Col E, Pastorino C, et al. Paraneoplastic autoimmune multi-organ syndrome: association with retroperitoneal Kaposi’s sarcoma. Acta Derm Venereol. 2016;96(2):261–2.PubMedGoogle Scholar
  39. 39.
    Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc. 2004;9(1):29–33.PubMedGoogle Scholar
  40. 40.
    Kimyai-Asadi A, Jih MH. Paraneoplastic pemphigus. Int J Dermatol. 2001;40(6):367–72.PubMedGoogle Scholar
  41. 41.
    Mutasim DF, Pelc NJ, Anhalt GJ. Paraneoplastic pemphigus. Dermatol Clin. 1993;11(3):473–81.PubMedGoogle Scholar
  42. 42.
    Zhu X, Zhang B. Paraneoplastic pemphigus. J Dermatol. 2007;34(8):503–11.PubMedGoogle Scholar
  43. 43.
    Namba C, Tohyama M, Hanakawa Y, Murakami M, Shirakata Y, Matsumoto T, et al. Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and intractable mucosal erosions: treatment with cyclosporin in addition to steroid, rituximab and intravenous immunoglobulin. J Dermatol. 2016;43(4):419–22.PubMedGoogle Scholar
  44. 44.
    Ghandi N, Ghanadan A, Azizian MR, Hejazi P, Aghazadeh N, Tavousi P, et al. Paraneoplastic pemphigus associated with inflammatory myofibroblastic tumour of the mediastinum: a favourable response to treatment and review of the literature. Australas J Dermatol. 2015;56(2):120–3.PubMedGoogle Scholar
  45. 45.
    Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Arch Dermatol. 1993;129(7):883–6.PubMedGoogle Scholar
  46. 46.
    Didona D, Paolino G, Richetta A, Cantisani C, Moliterni E, Calvieri S, et al. Paraneoplastic pemphigus: a trait d’union between dermatology and oncology. Adv Mod Oncol Res. 2015;1(2):7.Google Scholar
  47. 47.
    Descamps V, Belaich S. Paraneoplastic pemphigus. Presse Med. 1999;28(7):363–7.PubMedGoogle Scholar
  48. 48.
    Martel P, Joly P. Paraneoplastic pemphigus. Ann Dermatol Venereol. 2001;128(11):1256–9.PubMedGoogle Scholar
  49. 49.
    Preisz K, Karpati S. Paraneoplastic pemphigus. Orv Hetil. 2007;148(21):979–83.PubMedGoogle Scholar
  50. 50.
    Wang R, Li J, Wang M, Hao H, Chen X, Li R, et al. Prevalence of myasthenia gravis and associated autoantibodies in paraneoplastic pemphigus and their correlations with symptoms and prognosis. Br J Dermatol. 2015;172(4):968–75.PubMedGoogle Scholar
  51. 51.
    Leger S, Picard D, Ingen-Housz-Oro S, Arnault JP, Aubin F, Carsuzaa F, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012;148(10):1165–72.PubMedGoogle Scholar
  52. 52.
    Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001;66(2):142–4.PubMedGoogle Scholar
  53. 53.
    Kitagawa C, Nakajima K, Aoyama Y, Fujioka A, Nakajima H, Tarutani M, et al. A typical case of paraneoplastic pemphigus without detection of malignancy: effectiveness of plasma exchange. Acta Derm Venereol. 2014;94(3):359–61.PubMedGoogle Scholar
  54. 54.
    Williams JV, Marks JG Jr, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol. 2000;142(3):506–8.PubMedGoogle Scholar
  55. 55.
    Kershenovich R, Hodak E, Mimouni D. Diagnosis and classification of pemphigus and bullous pemphigoid. Autoimmun Rev. 2014;13(4–5):477–81.PubMedGoogle Scholar
  56. 56.
    Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320–32.PubMedGoogle Scholar
  57. 57.
    Laskaris G, Nicolis G. Immunopathology of oral mucosa in bullous pemphigoid. Oral Surg Oral Med Oral Pathol. 1980;50(4):340–5.PubMedGoogle Scholar
  58. 58.
    Chuah SY, Tan SH, Chua SH, Tang MB, Lim YL, Neoh CY, et al. A retrospective review of the therapeutic response with remission in patients with newly diagnosed bullous pemphigoid. Australas J Dermatol. 2014;55(2):149–51.PubMedGoogle Scholar
  59. 59.
    Hodge L, Marsden RA, Black MM, Bhogal B, Corbett MF. Bullous pemphigoid: the frequency of mucosal involvement and concurrent malignancy related to indirect immunofluorescence findings. Br J Dermatol. 1981;105(1):65–9.PubMedGoogle Scholar
  60. 60.
    Lo Schiavo A, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol. 2013;31(4):391–9.PubMedGoogle Scholar
  61. 61.
    Person JR, Rogers RS 3rd. Bullous and cicatricial pemphigoid. Clinical, histopathologic, and immunopathologic correlations. Mayo Clin Proc. 1977;52(1):54–66.PubMedGoogle Scholar
  62. 62.
    Shklar G, Meyer I, Zacarian SA. Oral lesions in bullous pemphigoid. Arch Dermatol. 1969;99(6):663–70.PubMedGoogle Scholar
  63. 63.
    Venning VA, Frith PA, Bron AJ, Millard PR, Wojnarowska F. Mucosal involvement in bullous and cicatricial pemphigoid. A clinical and immunopathological study. Br J Dermatol. 1988;118(1):7–15.PubMedGoogle Scholar
  64. 64.
    Williams DM. Vesiculo-bullous mucocutaneous disease: benign mucous membrane and bullous pemphigoid. J Oral Pathol Med. 1990;19(1):16–23.PubMedGoogle Scholar
  65. 65.
    Ghohestani RF, Nicolas JF, Rousselle P, Claudy AL. Identification of a 168-kDa mucosal antigen in a subset of patients with cicatricial pemphigoid. J Invest Dermatol. 1996;107(1):136–9.PubMedGoogle Scholar
  66. 66.
    Carrozzo M, Dametto E, Fasano ME, Broccoletti R, Carbone M, Rendine S, et al. Interleukin-4RA gene polymorphism is associated with oral mucous membrane pemphigoid. Oral Dis. 2014;20(3):275–80.PubMedGoogle Scholar
  67. 67.
    Oyama N, Setterfield JF, Powell AM, Sakuma-Oyama Y, Albert S, Bhogal BS, et al. Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol. 2006;154(1):90–8.PubMedGoogle Scholar
  68. 68.
    Rabelo DF, Nguyen T, Caufield BA, Ahmed AR. Mucous membrane pemphigoid in two half-sisters. The potential roles of autoantibodies to beta4 integrin subunits and HLA-DQbeta1*0301. J Dermatol Case Rep. 2014;8(1):9–12.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Xu HH, Werth VP, Parisi E, Sollecito TP. Mucous membrane pemphigoid. Dent Clin N Am. 2013;57(4):611–30.PubMedGoogle Scholar
  70. 70.
    Shklar G, McCarthy PL. Oral lesions of mucous membrane pemphigoid. A study of 85 cases. Arch Otolaryngol. 1971;93(4):354–64.PubMedGoogle Scholar
  71. 71.
    Grattan CE, Small D, Kennedy CT, Scully C. Oral herpes simplex infection in bullous pemphigoid. Oral Surg Oral Med Oral Pathol. 1986;61(1):40–3.PubMedGoogle Scholar
  72. 72.
    Maley A, Warren M, Haberman I, Swerlick R, Kharod-Dholakia B, Feldman R. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol. 2016;74(5):835–40.PubMedGoogle Scholar
  73. 73.
    Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370–9.PubMedGoogle Scholar
  74. 74.
    Setterfield J, Shirlaw PJ, Kerr-Muir M, Neill S, Bhogal BS, Morgan P, et al. Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease. Br J Dermatol. 1998;138(4):602–10.PubMedGoogle Scholar
  75. 75.
    Ali S, Kelly C, Challacombe SJ, Donaldson AN, Dart JK, Gleeson M, et al. Salivary IgA and IgG antibodies to bullous pemphigoid 180 noncollagenous domain 16a as diagnostic biomarkers in mucous membrane pemphigoid. Br J Dermatol. 2016;174(5):1022–9.PubMedGoogle Scholar
  76. 76.
    Sacher C, Hunzelmann N. Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches. Am J Clin Dermatol. 2005;6(2):93–103.PubMedGoogle Scholar
  77. 77.
    Canizares MJ, Smith DI, Conners MS, Maverick KJ, Heffernan MP. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol. 2006;142(11):1457–61.PubMedGoogle Scholar
  78. 78.
    Rogers RS 3rd. Mucous membrane pemphigoid. Dermatology at the millennium. Nashville: Parthenon Publishing; 1999. p. 5.Google Scholar
  79. 79.
    Hanson RD, Olsen KD, Rogers RS 3rd. Upper aerodigestive tract manifestations of cicatricial pemphigoid. Ann Otol Rhinol Laryngol. 1988;97(5 Pt 1):493–9.PubMedGoogle Scholar
  80. 80.
    Darling MR, Daley T. Blistering mucocutaneous diseases of the oral mucosa – a review: part 1. Mucous membrane pemphigoid. J Can Dent Assoc. 2005;71(11):851–4.PubMedGoogle Scholar
  81. 81.
    Di Zenzo G, Carrozzo M, Chan LS. Urban legend series: mucous membrane pemphigoid. Oral Dis. 2014;20(1):35–54.PubMedGoogle Scholar
  82. 82.
    Hayakawa T, Furumura M, Fukano H, Li X, Ishii N, Hamada T, et al. Diagnosis of oral mucous membrane pemphigoid by means of combined serologic testing. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117(4):483–96.PubMedGoogle Scholar
  83. 83.
    Messmer EM, Hintschich CR, Partscht K, Messer G, Kampik A. Ocular cicatricial pemphigoid. Retrospective analysis of risk factors and complications. Ophthalmologe. 2000;97(2):113–20.PubMedGoogle Scholar
  84. 84.
    Murrell DF, Marinovic B, Caux F, Prost C, Ahmed R, Wozniak K, et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol. 2015;72(1):168–74.PubMedGoogle Scholar
  85. 85.
    Rogers RS 3rd, Mehregan DA. Dapsone therapy of cicatricial pemphigoid. Semin Dermatol. 1988;7(3):201–5.PubMedGoogle Scholar
  86. 86.
    Rogers RS, Sheridan PJ, Jordon RE. Desquamative gingivitis. Clinical, histopathologic, and immunopathologic investigations. Oral Surg Oral Med Oral Pathol. 1976;42(3):316–27.PubMedGoogle Scholar
  87. 87.
    Rogers RS 3rd, Sheridan PJ, Nightingale SH. Desquamative gingivitis: clinical, histopathologic, immunopathologic, and therapeutic observations. J Am Acad Dermatol. 1982;7(6):729–35.PubMedGoogle Scholar
  88. 88.
    Scully C, Lo Muzio L. Oral mucosal diseases: mucous membrane pemphigoid. Br J Oral Maxillofac Surg. 2008;46(5):358–66.PubMedGoogle Scholar
  89. 89.
    Serrano TL, et al. Mucous membrane pemphigoid: diagnosis and sequel. Int Arch Otorhinolaryngol. 2014;18(S 01):1.Google Scholar
  90. 90.
    Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol. 2013;68(3):499–506.PubMedGoogle Scholar
  91. 91.
    Taylor J, McMillan R, Shephard M, Setterfield J, Ahmed R, Carrozzo M, et al. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucous membrane pemphigoid. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(2):161–71 e20.PubMedGoogle Scholar
  92. 92.
    Yeh SW, Usman AQ, Ahmed AR. Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy. Clin Immunol. 2004;112(3):268–72.PubMedGoogle Scholar
  93. 93.
    Greer RO, McDowell JD, Hoernig G. Oral lichen planus: a premalignant disease? Pro Pathol Case Rev. 1999;4:7.Google Scholar
  94. 94.
    Nagao T, Ikeda N, Fukano H, Hashimoto S, Shimozato K, Warnakulasuriya S. Incidence rates for oral leukoplakia and lichen planus in a Japanese population. J Oral Pathol Med. 2005;34(9):532–9.PubMedGoogle Scholar
  95. 95.
    Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin Dermatol. 2010;28(1):100–8.PubMedGoogle Scholar
  96. 96.
    Porter SR, Kirby A, Olsen I, Barrett W. Immunologic aspects of dermal and oral lichen planus: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83(3):358–66.PubMedGoogle Scholar
  97. 97.
    Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(2):164–78.PubMedGoogle Scholar
  98. 98.
    Au J, Patel D, Campbell JH. Oral lichen planus. Oral Maxillofac Surg Clin N Am. 2013;25(1):93–100.. viiGoogle Scholar
  99. 99.
    Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci. 2007;49(2):89–106.PubMedGoogle Scholar
  100. 100.
    Laeijendecker R, Dekker SK, Burger PM, Mulder PG, Van Joost T, Neumann MH. Oral lichen planus and allergy to dental amalgam restorations. Arch Dermatol. 2004;140(12):1434–8.PubMedGoogle Scholar
  101. 101.
    Olson MA, Rogers RS 3rd, Bruce AJ. Oral lichen planus. Clin Dermatol. 2016;34(4):495–504.PubMedGoogle Scholar
  102. 102.
    Parashar P. Oral lichen planus. Otolaryngol Clin N Am. 2011;44(1):89–107.. viGoogle Scholar
  103. 103.
    Pavlovsky L, Israeli M, Sagy E, Berg AL, David M, Shemer A, et al. Lichen planopilaris is associated with HLA DRB1*11 and DQB1*03 alleles. Acta Derm Venereol. 2015;95(2):177–80.PubMedGoogle Scholar
  104. 104.
    Sugerman PB, Savage NW, Zhou X, Walsh LJ, Bigby M. Oral lichen planus. Clin Dermatol. 2000;18(5):533–9.PubMedGoogle Scholar
  105. 105.
    Wetter DA, Davis MD. Recurrent erythema multiforme: clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007. J Am Acad Dermatol. 2010;62(1):45–53.PubMedGoogle Scholar
  106. 106.
    Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol. 1983;8(6):763–75.PubMedGoogle Scholar
  107. 107.
    Scully C, Bagan J. Oral mucosal diseases: erythema multiforme. Br J Oral Maxillofac Surg. 2008;46(2):90–5.PubMedGoogle Scholar
  108. 108.
    Ayangco L, Rogers RS 3rd. Oral manifestations of erythema multiforme. Dermatol Clin. 2003;21(1):195–205.PubMedGoogle Scholar
  109. 109.
    Lozada-Nur F, Gorsky M, Silverman S Jr. Oral erythema multiforme: clinical observations and treatment of 95 patients. Oral Surg Oral Med Oral Pathol. 1989;67(1):36–40.PubMedGoogle Scholar
  110. 110.
    Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol. 2012;51(8):889–902.PubMedGoogle Scholar
  111. 111.
    Leaute-Labreze C, Lamireau T, Chawki D, Maleville J, Taïeb A. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child. 2000;83(4):347–52.PubMedPubMedCentralGoogle Scholar
  112. 112.
    Bakis S, Zagarella S. Intermittent oral cyclosporin for recurrent herpes simplex-associated erythema multiforme. Australas J Dermatol. 2005;46(1):18–20.PubMedGoogle Scholar
  113. 113.
    Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131(5):539–43.PubMedGoogle Scholar
  114. 114.
    Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–6.PubMedGoogle Scholar
  115. 115.
    Brown RS. Oral erythema multiforme: trends and clinical findings of a large retrospective: European case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(6):681.PubMedGoogle Scholar
  116. 116.
    Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. 2015;72(2):239–45.PubMedGoogle Scholar
  117. 117.
    Celentano A, Tovaru S, Yap T, Adamo D, Aria M, Mignogna MD. Oral erythema multiforme: trends and clinical findings of a large retrospective European case series. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(6):707–16.PubMedGoogle Scholar
  118. 118.
    Joseph RH, Haddad FA, Matthews AL, Maroufi A, Monroe B, Reynolds M. Erythema multiforme after orf virus infection: a report of two cases and literature review. Epidemiol Infect. 2015;143(2):385–90.PubMedGoogle Scholar
  119. 119.
    Joseph TI, Vargheese G, George D, Sathyan P. Drug induced oral erythema multiforme: a rare and less recognized variant of erythema multiforme. J Oral Maxillofac Pathol. 2012;16(1):145–8.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Kishore BN, Ankadavar NS, Kamath GH, Martis J. Varicella zoster with erythema multiforme in a young girl: a rare association. Indian J Dermatol. 2014;59(3):299–301.PubMedPubMedCentralGoogle Scholar
  121. 121.
    Patil B, Hegde S, Naik S, Sharma R. Oral blistering – report of two cases of erythema multiforme & literature review. J Clin Diagn Res. 2013;7(9):2080–3.PubMedPubMedCentralGoogle Scholar
  122. 122.
    Rogers RS 3rd. Pseudo-Behcet’s disease. Dermatol Clin. 2003;21(1):49–61.PubMedGoogle Scholar
  123. 123.
    Samim F, Auluck A, Zed C, Williams PM. Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment. Dent Clin N Am. 2013;57(4):583–96.PubMedGoogle Scholar
  124. 124.
    Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69(2):173 e1–13.. quiz 185–6Google Scholar
  125. 125.
    Mittmann N, Knowles SR, Koo M, Shear NH, Rachlis A, Rourke SB. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012;13(1):49–54.PubMedGoogle Scholar
  126. 126.
    Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–53.PubMedGoogle Scholar
  127. 127.
    Lu N, Rai SK, Terkeltaub R, Kim SC, Menendez ME, Choi HK. Racial disparities in the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. Semin Arthritis Rheum. 2016;46(2):253–8.PubMedPubMedCentralGoogle Scholar
  128. 128.
    Miliszewski MA, Kirchhof MG, Sikora S, Papp A, Dutz JP. Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention. Am J Med. 2016;129(11):1221–5.PubMedGoogle Scholar
  129. 129.
    Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013;69(2):187 e1–16.. quiz 203–4Google Scholar
  130. 130.
    Stern RS. Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysis. JAMA. 2014;312(15):1590–1.PubMedGoogle Scholar
  131. 131.
    Salmi TT, Hervonen K, Kautiainen H, Collin P, Reunala T. Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study from Finland. Br J Dermatol. 2011;165(2):354–9.PubMedGoogle Scholar
  132. 132.
    Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part I. Epidemiology, pathogenesis, and clinical presentation. J Am Acad Dermatol. 2011;64(6):1017–24; quiz 1025–6PubMedGoogle Scholar
  133. 133.
    Smith JB, Tulloch JE, Meyer LJ, Zone JJ. The incidence and prevalence of dermatitis herpetiformis in Utah. Arch Dermatol. 1992;128(12):1608–10.PubMedGoogle Scholar
  134. 134.
    Karpati S. Dermatitis herpetiformis: close to unravelling a disease. J Dermatol Sci. 2004;34(2):83–90.PubMedGoogle Scholar
  135. 135.
    Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis. J Am Acad Dermatol. 2011;64(6):1027–33; quiz 1033–4PubMedGoogle Scholar
  136. 136.
    Peters MS, McEvoy MT. IgA antiendomysial antibodies in dermatitis herpetiformis. J Am Acad Dermatol. 1989;21(6):1225–31.PubMedGoogle Scholar
  137. 137.
    Dieterich W, Laag E, Bruckner-Tuderman L, Reunala T, Kárpáti S, Zágoni T, et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol. 1999;113(1):133–6.PubMedGoogle Scholar
  138. 138.
    Griffiths CE, Leonard JN, Fry L. Dermatitis herpetiformis exacerbated by indomethacin. Br J Dermatol. 1985;112(4):443–5.PubMedGoogle Scholar
  139. 139.
    Bardella MT, Fredella C, Saladino V, Trovato C, Cesana BM, Quatrini M, et al. Gluten intolerance: gender- and age-related differences in symptoms. Scand J Gastroenterol. 2005;40(1):15–9.PubMedGoogle Scholar
  140. 140.
    Economopoulou P, Laskaris G. Dermatitis herpetiformis: oral lesions as an early manifestation. Oral Surg Oral Med Oral Pathol. 1986;62(1):77–80.PubMedGoogle Scholar
  141. 141.
    Fraser NG, Kerr NW, Donald D. Oral lesions in dermatitis herpetiformis. Br J Dermatol. 1973;89(5):439–50.PubMedGoogle Scholar
  142. 142.
    Sansaricqa FC, Petronic-Rosic V. Dermatitis herpetiformis: what practitioners need to know. Pract Gastr. 2012;111:39–44.Google Scholar
  143. 143.
    Hietanen J, Reunala T. IgA deposits in the oral mucosa of patients with dermatitis herpetiformis and linear IgA disease. Scand J Dent Res. 1984;92(3):230–4.PubMedGoogle Scholar
  144. 144.
    Katz SI. Dermatitis herpetiformis. Clinical, histologic, therapeutic and laboratory clues. Int J Dermatol. 1978;17(7):529–35.PubMedGoogle Scholar
  145. 145.
    Nicolas ME, Krause PK, Gibson LE, Murray JA. Dermatitis herpetiformis. Int J Dermatol. 2003;42(8):588–600.PubMedGoogle Scholar
  146. 146.
    Nisengard RJ, Chorzelski T, Maciejowska E, Kryst L. Dermatitis herpetiformis: IgA deposits in gingiva, buccal mucosa, and skin. Oral Surg Oral Med Oral Pathol. 1982;54(1):22–5.PubMedGoogle Scholar
  147. 147.
    Sawant P, Kshar A, Byakodi R, Paranjpe A. Immunofluorescence in oral mucosal diseases –a review. Oral Surg Oral Med Oral Radiol. 2014;2(1):5.Google Scholar
  148. 148.
    Chan LS, Regezi JA, Cooper KD. Oral manifestations of linear IgA disease. J Am Acad Dermatol. 1990;22(2 Pt 2):362–5.PubMedGoogle Scholar
  149. 149.
    Kelly SE, Frith PA, Millard PR, Wojnarowska F, Black MM. A clinicopathological study of mucosal involvement in linear IgA disease. Br J Dermatol. 1988;119(2):161–70.PubMedGoogle Scholar
  150. 150.
    Leonard JN, Wright P, Williams DM, Gilkes JJ, Haffenden GP, McMinn RM, et al. The relationship between linear IgA disease and benign mucous membrane pemphigoid. Br J Dermatol. 1984;110(3):307–14.PubMedGoogle Scholar
  151. 151.
    Porter SR, Bain SE, Scully CM. Linear IgA disease manifesting as recalcitrant desquamative gingivitis. Oral Surg Oral Med Oral Pathol. 1992;74(2):179–82.PubMedGoogle Scholar
  152. 152.
    O’Regan E, Bane A, Flint S, Timon C, Toner M. Linear IgA disease presenting as desquamative gingivitis: a pattern poorly recognized in medicine. Arch Otolaryngol Head Neck Surg. 2004;130(4):469–72.PubMedGoogle Scholar
  153. 153.
    Fine JD, Neises GR, Katz SI. Immunofluorescence and immunoelectron microscopic studies in cicatricial pemphigoid. J Invest Dermatol. 1984;82(1):39–43.PubMedGoogle Scholar
  154. 154.
    Coelho S, Tellechea O, Reis JP, Mariano A, Figueiredo A. Vancomycin-associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. Int J Dermatol. 2006;45(8):995–6.PubMedGoogle Scholar
  155. 155.
    Cohen DM, Bhattacharyya I, Zunt SL, Tomich CE. Linear IgA disease histopathologically and clinically masquerading as lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88(2):196–201.PubMedGoogle Scholar
  156. 156.
    Green ST, Natarajan S. Linear IgA disease and oesophageal carcinoma. J R Soc Med. 1987;80(1):48–9.PubMedPubMedCentralGoogle Scholar
  157. 157.
    Marinkovich MP, Taylor TB, Keene DR, Burgeson RE, Zone JJ. LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol. 1996;106(4):734–8.PubMedGoogle Scholar
  158. 158.
    McEvoy MT, Connolly SM. Linear IgA dermatosis: association with malignancy. J Am Acad Dermatol. 1990;22(1):59–63.PubMedGoogle Scholar
  159. 159.
    Ongole R, Praveen BN, editors. Textbook of oral medicine, oral diagnosis and oral radiology. 2nd ed. New Delhi: Elsevier India; 2014. p. 924.Google Scholar
  160. 160.
    Sago J, Hall RP. Dapsone. Dermatol Ther. 2002;15:11.Google Scholar
  161. 161.
    Yomada M, Komai A, Hashimato T. Sublamina densa-type linear IgA bullous dermatosis successfully treated with oral tetracycline and niacinamide. Br J Dermatol. 1999;141(3):608–9.PubMedGoogle Scholar
  162. 162.
    Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, et al. The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol. 2008;58(6):931–50.PubMedGoogle Scholar
  163. 163.
    Intong LR, Murrell DF. Inherited epidermolysis bullosa: new diagnostic criteria and classification. Clin Dermatol. 2012;30(1):70–7.PubMedGoogle Scholar
  164. 164.
    Youssefian L, Vahidnezhad H, Uitto J. Kindler syndrome. In: Pagon RA, et al., editors. GeneReviews (R). Seattle: University of Washington; 1993.Google Scholar
  165. 165.
    Murauer EM, Koller U, Pellegrini G, De Luca M, Bauer JW. Advances in gene/cell therapy in epidermolysis bullosa. Keio J Med. 2015;64(2):21–5.PubMedGoogle Scholar
  166. 166.
    Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, Xia L, et al. TALEN-based gene correction for epidermolysis bullosa. Mol Ther. 2013;21(6):1151–9.PubMedPubMedCentralGoogle Scholar
  167. 167.
    Tolar J, McGrath JA, Xia L, Riddle MJ, Lees CJ, Eide C, et al. Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2014;134(5):1246–54.PubMedGoogle Scholar
  168. 168.
    Aberdam D, Aguzzi A, Baudoin C, Galliano MF, Ortonne JP, Meneguzzi G. Developmental expression of nicein adhesion protein (laminin-5) subunits suggests multiple morphogenic roles. Cell Adhes Commun. 1994;2(2):115–29.PubMedGoogle Scholar
  169. 169.
    Asaka T, Akiyama M, Domon T, Nishie W, Natsuga K, Fujita Y, et al. Type XVII collagen is a key player in tooth enamel formation. Am J Pathol. 2009;174(1):91–100.PubMedPubMedCentralGoogle Scholar
  170. 170.
    Kudva P, Jain R. Periodontal manifestation of epidermolysis bullosa: looking through the lens. J Indian Soc Periodontol. 2016;20(1):72–4.PubMedPubMedCentralGoogle Scholar
  171. 171.
    Siegel DH, Ashton GH, Penagos HG, Lee JV, Feiler HS, Wilhelmsen KC, et al. Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome. Am J Hum Genet. 2003;73(1):174–87.PubMedPubMedCentralGoogle Scholar
  172. 172.
    Wright JT. Oral manifestations in the epidermolysis bullosa spectrum. Dermatol Clin. 2010;28(1):159–64.PubMedPubMedCentralGoogle Scholar
  173. 173.
    Wright JT, Fine JD, Johnson LB. Oral soft tissues in hereditary epidermolysis bullosa. Oral Surg Oral Med Oral Pathol. 1991;71(4):440–6.PubMedGoogle Scholar
  174. 174.
    Stephenson P, Lamey PJ, Scully C, Prime SS. Angina bullosa haemorrhagica: clinical and laboratory features in 30 patients. Oral Surg Oral Med Oral Pathol. 1987;63(5):560–5.PubMedGoogle Scholar
  175. 175.
    High AS, Main DM. Angina bullosa haemorrhagica: a complication of long-term steroid inhaler use. Br Dent J. 1988;165(5):176–9.PubMedGoogle Scholar
  176. 176.
    Kurban M, Kibbi AG, Ghosn S. Expanding the histologic spectrum of angina bullosa hemorrhagica: report of one case. Am J Dermatopathol. 2007;29(5):477–9.PubMedGoogle Scholar
  177. 177.
    Shashikumar B, Reddy RR, Harish M. Oral hemorrhagic blister: an enigma. Indian J Dermatol. 2013;58(5):407.PubMedPubMedCentralGoogle Scholar
  178. 178.
    Shoor H, Mutalik S, Pai KM. Angina bullosa haemorrhagica. BMJ Case Rep. 2013;2013:bcr2013200352.PubMedPubMedCentralGoogle Scholar
  179. 179.
    Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91.PubMedGoogle Scholar
  180. 180.
    Nagarajan A, Masthan MK, Sankar LS, Narayanasamy AB, Elumalai R. Oral manifestations of vitiligo. Indian J Dermatol. 2015;60(1):103.PubMedPubMedCentralGoogle Scholar
  181. 181.
    Lawoyin D, Brown R, Reid E, Sam F, Obayomi T. Concurrent presentation of cutaneous and oral soft tissue vitiligo: a case report and literature review. Int J Dent Sci. 2007;5:5.Google Scholar
  182. 182.
    Dawber RP. Clinical associations of vitiligo. Postgrad Med J. 1970;46(535):276–7.PubMedPubMedCentralGoogle Scholar
  183. 183.
    Bordere AC, Lambert J, van Geel N. Current and emerging therapy for the management of vitiligo. Clin Cosmet Investig Dermatol. 2009;2:15–25.PubMedPubMedCentralGoogle Scholar
  184. 184.
    Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: a comprehensive overview Part II: treatment options and approach to treatment. J Am Acad Dermatol. 2011;65(3):493–514.PubMedGoogle Scholar
  185. 185.
    Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159(5):1051–76.PubMedGoogle Scholar
  186. 186.
    Whitton ME, Ashcroft DM, Gonzalez U. Therapeutic interventions for vitiligo. J Am Acad Dermatol. 2008;59(4):713–7.PubMedGoogle Scholar
  187. 187.
    Al-Otaibi SR, Zadeh VB, Al-Abdulrazzaq AH, Tarrab SM, Al-Owaidi HA, Mahrous R, et al. Using a 308-nm excimer laser to treat vitiligo in Asians. Acta Dermatovenerol Alp Pannonica Adriat. 2009;18(1):13–9.PubMedGoogle Scholar
  188. 188.
    Ashok N, Karunakaran A, Singh P, Rodrigues J, Ashok N, Tarakji B, et al. Gingival vitiligo: report of a case and review of the literature. Case Rep Dent. 2014;2014:874025.PubMedPubMedCentralGoogle Scholar
  189. 189.
    Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. Acta Derm Venereol. 1997;77(6):460–2.PubMedGoogle Scholar
  190. 190.
    Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol. 2003;28(3):285–7.PubMedGoogle Scholar
  191. 191.
    Parsad D, Kanwar A. Oral minocycline in the treatment of vitiligo – a preliminary study. Dermatol Ther. 2010;23(3):305–7.PubMedGoogle Scholar
  192. 192.
    Dave S, Thappa DM, Dsouza M. Clinical predictors of outcome in vitiligo. Indian J Dermatol Venereol Leprol. 2002;68(6):323–5.PubMedGoogle Scholar
  193. 193.
    McHepange UO, Gao XH, Liu YY, Liu YB, Ma L, Zhang L, Chen HD. Vitiligo in North-Eastern China: an association between mucosal and acrofacial lesions. Acta Derm Venereol. 2010;90(2):136–40.PubMedGoogle Scholar
  194. 194.
    Powell FC, Dicken CH. Psoriasis and vitiligo. Acta Derm Venereol. 1983;63(3):246–9.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Michael Z. Wang
    • 1
  • Julia S. Lehman
    • 2
    Email author
  • Roy Steele RogersIII
    • 3
  1. 1.Department of DermatologyMayo ClinicRochesterUSA
  2. 2.Departments of Dermatology and Laboratory Medicine and PathologyMayo ClinicRochesterUSA
  3. 3.Department of DermatologyMayo Clinic ArizonaScottsdaleUSA

Personalised recommendations